Floatz Rating
B63/100
Confidence
Indicative
Sponsor
IFOM ETS - The AIRC Institute of Molecular Oncology
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
62High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06490536CT.gov The Sagittarius Trial | — | Recruiting | — | — | — |
NCT05121038CT.gov CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab | — | Active Not Recruiting | — | — | — |
NCT03442569CT.gov PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC | — | Completed | — | — | — |
NCT00788957CT.gov Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC) | — | Completed | — | — | — |
NCT00630786CT.gov Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study | — | Completed | — | — | — |
NCT00332163CT.gov Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy | — | Completed | — | — | — |
NCT00101894CT.gov Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colon Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Panitumumab (this asset) | IFOM ETS - The AIRC Institute of Molecular Oncology | P3 | B · 63 |
| Floxuridine | City of Hope Medical Center | P2 | BBB |
| Oxaliplatin | Sun Yat-sen University | P3 | BB |
| Fluorouracilum | Akeso | P4 | BB |
| Pertuzumab | IFOM ETS - The AIRC Institute of Molecular Oncology | P3 | BB |
| Encorafenib | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | P3 | BB |
| Trastuzumab | IFOM ETS - The AIRC Institute of Molecular Oncology | P3 | BB |
| Irinotecan | SCRI Development Innovations, LLC | P3 | BB |
| Palbociclib | Lebanese University | P2 | BB |
+42 more in the Colon Carcinoma cohort
Other indications for Panitumumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Neoplasm | — | P2 | BBB · 73 |
| Colorectal Cancer | — | P3 | BB · 68 |
| Rectal Carcinoma | — | P2 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Panitumumab in Colon Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/panitumumab-colon-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →